This document is a news release from Merck & Co., Inc. that outlines their second-quarter 2025 financial results. It details worldwide sales figures, highlighting performance of key products like KEYTRUDA and GARDASIL/GARDASIL 9, and provides GAAP and Non-GAAP earnings per share (EPS). The release also announces significant strategic initiatives, including the acquisition of Verona Pharma, positive clinical trial results for new treatments, and a multiyear optimization initiative aimed at cost savings and reinvestment into growth areas. Finally, it updates the full-year 2025 financial outlook and provides an overview of pipeline advancements across various therapeutic areas.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana